Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam-Reference-Cited by-同舟云学术

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam

Published:2019-08 Issue:8 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Belley Adam¹,Huband Michael D.²,Fedler Kelley A.²,Watters Amy A.²,Flamm Robert K.²,Shapiro Stuart¹,Knechtle Philipp¹

Affiliation:

1. Allecra Therapeutics SAS, Saint-Louis, France

2. JMI Laboratories, North Liberty, Iowa, USA

Abstract

Third-generation cephalosporin resistance among Enterobacteriaceae , mediated by the spread of extended-spectrum β-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone β-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00607-19

Reference34 articles.

1. Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

2. The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world

3. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014

4. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

5. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Staphylococcus aureus potential of compounds from Ganoderma sp.: A comprehensive molecular docking and simulation approaches;Heliyon;2024-04

2. Integrating in Silico and In Vitro Studies to Screen Anti-Staphylococcus aureus Activity From Vietnamese Ganoderma multiplicatum and Ganoderma sinense;Natural Product Communications;2023-04

3. Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening;AMB Express;2022-12-01

4. Antibióticos en desarrollo para bacilos gram negativos multirresistentes;Medicina Intensiva;2022-11

5. Variability of Beta-Lactam Broth Microdilution for Pseudomonas aeruginosa;Antimicrobial Agents and Chemotherapy;2021-09-17